Alpha-1 Antitrypsin Deficiency (AATD)
What is Alpha-1 Antitrypsin Deficiency?
AATD is an inherited, genetic, autosomal co-dominant disorder caused by mutations in the SERPINA1 gene, with the most frequent deficient variants coming from the Z (Glu342Lys) and S alleles (Glu264Val). The presence of Z alleles results in misfolding and polymerization of the AAT, leading to over 95% of severe AATD patients being PIZZ.
About YOLT-202
YOLT-202 is an in vivo gene-editing therapy that corrects PiZ mutation to PiM for the treatment of AATD. Utilizing YolTech’s proprietary adenine base editor, YOLT-202 is engineered to achieve on-target editing with minimal bystander activity.
Latest News
-
Sep 07, 2026
YolTech Presented Proof-of-Concept Data from Clinical Trial of YOLT-202 in PiZZ Alpha-1 Antitrypsin Deficiency (AATD) Patients at European Respiratory Society Congress 2026Read More
-
Sep 05, 2026
YolTech to Present Late-Breaking Proof-of-Concept Clinical Data from YOLT-202 Clinical Trial in PiZZ Alpha-1 Antitrypsin Deficiency (AATD) Patients at European Respiratory Society Congress 2026Read More
-
Aug 27, 2026
YolTech to Present Positive Data from Clinical Trial of YOLT-201 in ATTR-CM Patients at European Society of Cardiology Congress 2026Read More
